KNSA Kiniksa Pharmaceuticals

Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis

Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis
EN
06/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kiniksa Pharmaceuticals

 PRESS RELEASE

Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care...

Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 3:10 p.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event. About KiniksaKiniksa is a biopharmaceutical compan...

Wedbush Research
  • Wedbush Research
 PRESS RELEASE

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Fina...

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution – ARCALYST® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by the end of 2026 –– Cash balance increased by $170.4 million in 2025 to $414.1 million –      – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. ...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
Wedbush Research
  • Wedbush Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch